With a no-deal Brexit still a real possibility, Merck continues to prepare for the worst case scenario.
James Strachan | | Longer Read
In April, the European Council granted the UK an extension of the Article 50 deadline to October 31. This averted a no-deal exit whereby the UK would become a “third country” overnight – at least for the time being. Since then, the British Prime Minister, Theresa May resigned, prompting a leadership contest. At the time of writing, we still have little idea how the first stage of the Brexit process will conclude, with deal, no deal, and perhaps even no Brexit, all still on the cards. This means pharmaceutical companies must continue to prepare for the worst case scenario – that the EU Treaties will cease to apply to the UK on October 31.
We speak with Frithjof Holtz, an expert in Advocacy & Surveillance in Regulatory Management at Merck Life Science, and head of Merck Life Science’s Brexit mitigation project to find out which issues have troubled Merck the most and what they have been doing – and continue to do – to mitigate the risks.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.
- Merck KGaA, “BREXIT FAQ” (2019). Available at: https://bit.ly/2XnV120. Last accessed, July 4, 2019.